CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0277872 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Guang Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dalian Key Laboratory of Reproduction and Mother-child Genetic, Reproductive & Genetic Medicine Center, Dalian Women and Children's Med…. Hauptthemen laut MEDLINE: Carcinoma, Endometrioid, Endometrial Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
Uterine corpus endometrial carcinoma (UCEC) is one of the most common type of gynecological malignancies. Multiple lines of evidence indicated that CXC chemokines exerted an anti-tumor immunological role in the tumor microenvironment which were critical regulators of cancer immunity. However, the relevance of CXC chemokines in the evaluation of prognosis and immune infiltration of UCEC remains to be explored. This study utilized various online databases, including TCGA, UALCAN, Kaplan-Meier Plotter, cBioPortal, TIMER2.0, TISIDB, and MethSurv to perform the analysis. Gene expression data from the TCGA-UCEC dataset indicated decreased expression of CXCL2/12 and increased expression of CXCL14/17. CXCL2/12 expression was negatively whereas CXCL14/17 expression was positively correlated with clinicopathological features of UCEC patients, including cancer stage, patients’ age, weight and menopause status. Patients with higher CXCL12/14 expression corresponded with better clinical outcomes, which were not influenced by the genetic alterations. The differential expression of CXCL2/12/14/17 was not only significantly correlated with immune infiltration levels, but also the abundance of immune checkpoint inhibitors. Heatmaps of DNA methylation of CXCL2/12/14/17 were investigated, and 4 CpGs of CXCL2, 16 CpGs of CXCL12, 3 CpGs of CXCL14/17 were identified where altered methylation affected the prognosis of UCEC patients. These findings provided novel insights into the immunologic features of UCEC and might pave the way toward the prognostic evaluation and immunotherapy selection based on CXCL2/12/14/17 expression status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dalian Key Laboratory of Reproduction and Mother-child Genetic, Reproductive & Genetic Medicine Center, Dalian Women and Children's Medical Group, Dalian, Liaoning Province, China.
- Department of Obstetrics and Gynecology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
- Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
- Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, Liaoning Province, China.
ORCID-Profile: Qin Zheng
Förderung
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Wang, G., Fu, J., Liu, M., & Zheng, Q. (2024). CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0277872
Vancouver
Wang G, Fu J, Liu M, Zheng Q. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0277872
BibTeX
@article{Wang2024,
author = {Wang, Guang and Fu, Juan and Liu, Mulin and Zheng, Qin},
title = {CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0277872}
}
EUVIMED